Manara - Qatar Research Repository
Browse
000505686.pdf (377.04 kB)

Acute Myeloid Leukemia after Low-Dose Radioiodine Therapy for Papillary Thyroid Carcinoma

Download (377.04 kB)
journal contribution
submitted on 2024-02-27, 08:12 and posted on 2024-02-27, 08:12 authored by Arwa Alsaud, Shehab Mohamed, Mohamed A. Yassin, Amr Ashour, Khaldun Obeidat, Bahjat Azrieh

Papillary thyroid carcinoma is the most common primary thyroid cancer. Most frequently treated with surgical resection, some cases require radioactive iodine (RAI) therapy. Studies have suggested that there is an increase in second primary malignancy after RAI therapy amongst thyroid cancer survivors including acute myeloid leukemia (AML) as an infrequent cancer related to RAI therapy; it has a higher relative risk ratio in patients on higher doses of radiation exposure. We would like to report a 30-year-old lady who was diagnosed with papillary thyroid carcinoma. She underwent total thyroidectomy and received a low-dose RAI 131I therapy at a dose of 150 mCi, after which she developed therapy-related AML. Here we would like to highlight the association of AML with low-dose RAI as an infrequent cause of a second primary tumor compared to high doses.

Other Information

Published in: Case Reports in Oncology
License: https://creativecommons.org/licenses/by-nc/4.0/
See article on publisher's website: https://dx.doi.org/10.1159/000505686

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Karger

Publication Year

  • 2020

License statement

This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License

Institution affiliated with

  • Hamad Medical Corporation

Usage metrics

    Hamad Medical Corporation

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC